BIOMAT Database Logo BIOMAT Database Logo

Wegener's granulomatosis in a patient with severe PiZZ alpha 1-antitrypsin deficiency. 1996

A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014890 Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN. Granulomatosis, Wegener's,Wegener Granulomatosis,Wegener's Granulomatosis,Granulomatosis with Polyangiitides,Granulomatosis, Wegener,Polyangiitides, Granulomatosis with,Polyangiitis, Granulomatosis with,with Polyangiitides, Granulomatosis,with Polyangiitis, Granulomatosis
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents
D019896 alpha 1-Antitrypsin Deficiency Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS. Deficiencies, alpha 1-Antitrypsin,Deficiency, alpha 1-Antitrypsin,alpha 1 Antitrypsin Deficiency,alpha 1-Antitrypsin Deficiencies

Related Publications

A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Survival in severe alpha-1-antitrypsin deficiency (PiZZ).
April 2010, Respiratory research,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Neurologic manifestations in Wegener's granulomatosis associated with alpha 1-antitrypsin deficiency.
September 1993, Neurology,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.
January 1988, Journal of clinical epidemiology,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Liver disease in children with PiZZ alpha 1-antitrypsin deficiency.
January 1988, Hepatology (Baltimore, Md.),
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida).
December 2002, European journal of gastroenterology & hepatology,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
PiZZ alpha 1-antitrypsin deficiency in a 20-week fetus.
February 1985, Human pathology,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).
December 2008, Thorax,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).
August 2002, Thorax,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Bilateral central retinal artery occlusion in Wegener's granulomatosis and alpha(1) antitrypsin deficiency.
April 2002, The British journal of ophthalmology,
A N Elzouki, and M Segalmark, and P Mazodier, and S Eriksson
Acquired PiZZ alpha-1 antitrypsin deficiency in a liver transplant recipient.
June 2004, Transplantation,
Copied contents to your clipboard!